Interpretation of Drug Risk and Benefit: Individual and Population Perspectives

Annals of Pharmacotherapy

Volumn 38, Issue 4, 2004, Pages 694-699

  Bjornson, Darrel C ^a,b  

^a DRAKE UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Drug benefit; Drug risk

Indexed keywords

DECISION MAKING; EVIDENCE BASED MEDICINE; PHARMACY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; TREATMENT PLANNING;

CLINICAL TRIALS; DECISION MAKING; DRUG THERAPY; ODDS RATIO; PATIENT CARE MANAGEMENT; PHARMACEUTICAL PREPARATIONS; PHARMACISTS; RESEARCH DESIGN; RISK ASSESSMENT; TERMINOLOGY;

EID: 1542429163     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D401     Document Type: Review

References (14)

1. Waning B, Montagne M. Pharmacoepidemiology - principles and practice. New York: McGraw-Hill, 2002.
2. Fletcher RH, Fletcher SW, Wagner EH. Clinical epidemiology - the essentials. 3rd ed. Baltimore: Williams and Wilkins, 1996.
3. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia: Lippincott-Raven, 1997.
4. Naylor CD, Chen E, Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med 1992;117:916-21.
5. Forrow L, Taylor WC, Arnold RM. Absolutely relative: how research results are summarized can affect treatment decisions. Am J Med 1992;92:121-4.
6. Nuevo J, Melnikov J, Chang D. Reporting number needed to treat and absolute risk reduction in randomized controlled trials. JAMA 2002;287:2813-4.
7. Elting LS, Martin CG, Cantor SB, Rubenstein EB. Influence of data display formats on physician investigator's decisions to stop clinical trials. BMJ 1999;318:1527-31.
8. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4.
9. Chatellier G, Zapletal E, Lemaitre D, Menard J, Degoulet P. The number needed to treat: a clinically useful nomogram in its proper context. BMJ 1996;312:426-9.
10. Bucher HC, Weinbacher M, Gyr K. Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration. BMJ 1994;309:761-4.
11. Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998;129:681-9.
12. Moher D, Schulz KF, Altman D, CONSORT group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. JAMA 2001;285:1987-91.
13. Yoke YK, Bell A, Derry S. Aspirin for the prevention of cardiovascular disease: calculating benefit and harm in the individual patient. Br J Clin Pharmacol 2003;55:282-7.
14. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women - principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.